Cytokines have been widely used as adjuvants and therapeutic agents in treatments of human diseases. Despite their recognized potential as drugs, the medical use of cytokines has considerable drawbacks, mainly related to their low stability and short half-life. Such intrinsic limitations imply the administration of high doses, often prompting toxicity, undesirable side effects and greater production costs. Here, we describe a new category of mechanically stable nanostructured cytokines (TNFand CCL4/MIP-1) that resist harsh physicochemical conditions in vitro (pH and temperature), while maintaining functionality. These bio-functional materials are produced in recombinant cell factories through cost-effective and fully scalable processes. Notably, we demonstrate their prophylactic potential in vivo showing they protect zebrafish from a lethal infection by Pseudomonas aeruginosa.
Introduction
In the quest for safe, effective, practical prophylactics and therapeutics, recombinant proteins are provoking wide interest. Prophylactics such as subunit vaccines or therapeutics such as immunostimulants, are examples of successfully produced proteins.
Both are functionally well-characterized products, which are superior to DNA vaccines or inactivated/attenuated vaccines in terms of biosafety. Additionally, they are poorly reactogenic and can be designed a la carte [1] . Heterologous protein expression systems allow for easy and highly reproducible protein production at lower cost and at large scale [2] . Such systems have been developed in bacteria (E. coli), yeast (S. cerevisiae), insect cells (D. melanogaster cells), protozoa (Tetrahymena thermophila), mammalian cell cultures or plants [3, 4] . In bacterial expression systems, in many cases, the desired protein product needs to be extracted from inclusion bodies (IBs) and renaturalized to obtain the soluble form. Recently IBs, per se, have attracted interest as bio-materials due to their high stability, withstanding extreme temperatures and lyophilization [5] . IBs are protein clusters in the upper size of the nanoscale, ranging from 50 to 700 nm [6] , highly enriched with the recombinant protein itself but complex in composition, including a spectrum of macromolecules from the producing cell. Nevertheless, IBs are not inert and when exposed to mammalian cells penetrate the membrane and they issue a sustained release of the protein they are comprised of, in a functional form, over time [7] . This fact has been previously demonstrated with a diversity of proteins forming IBs, including hormones, chaperones, enzymes, growth factors and cytoskeleton components [7] [8] [9] [10] . Most of the biological and physicochemical properties of IBs are moldable, such as size, bio-adhesiveness, net charge, density and the release of functional protein inside cells upon exposure [5, [11] [12] [13] . Importantly, the recombinant protein production of IBs is fully scalable and the biofabrication process is cost-effective.
Cytokines are proteins with a central role in immunity [14] and have been used as adjuvants, immunostimulants and therapeutic agents in the treatment of human diseases [15] [16] [17] . Their biomedical use is associated to their involvement in the pathogenesis of many diseases; the fact that they are unlikely to elicit an allergic response and that they are able to stimulate the immune system without the presence of a pathogen. Different cytokines have been tested as treatments for various diseases. Interferon alpha (IFNα) is one of the best characterized cytokines for human disease treatment [18] and can be naturally derived (leukocyte or lymphoblastoid derived) or recombinantly produced (E.
coli-derived). Therapeutic uses of IFNα include hepatitis B and C (antiviral), condyloma
(immunomodulation), Kaposi's sarcoma (antiangiogenic) and hairy cell-leukemia (antitumor) [17, 18] . IL-2 is another example of a cytokine that has been obtained from E. coli and evaluated as a therapeutic in bladder carcinoma and melanoma [16, 17] .
TNFα has been produced recombinantly in E. coli and different studies have revealed it exhibits antitumor properties and strong hemodynamic effects. In fact, TNFα has been used to treat cancer in phase III studies in melanoma patients [19] . CCL4 induces monocyte cell recruitment at inflammatory sites [20] but clinical studies are still being conducted to confirm the pathophysiological role of CCL4 as an active factor in ischaemic stroke, as a neuroprotective agent or as an anti-HIV agent [21, 22] .
Additionally, other cytokines have been explored as a potential therapeutics, such as CCL5, IL-6, IL-7, IL-15, IFNβ [23] [24] [25] but only a few recombinant cytokines such as G-CSF, GM-CSF, erythropoietin or IL-2 have been licensed for human use [1, 26] .
Despite all their appealing therapeutic properties, cytokines have significant drawbacks for medical use, in particular their short half-life (minutes or hours), which implies the administration of high doses, prompting toxicity and systemic effects as cytokines are administrated intravenously. Further, high doses entail the expensive production of large quantities [27, 28] .
In this study, we have explored the ability of tumor necrosis factor alpha (TNF and chemokine (C-C motif) ligand 4 (CCL4) produced as nanostructured functional IBs, to act as immunostimulants and potential adjuvants. By using cytokines in the form of nanostructured IBs, we hope to overcome the fundamental difficulties of poor stability and short half-life, which hinder cytokine use. We show that nanostructured recombinant cytokines are easy to produce by cost-effective and highly reproducible procedures. Furthermore, we provide detailed evidence in the model organism zebrafish (Danio rerio), that they can be used in vivo as efficient immunostimulants or adjuvants, either injected or orally administrated, inducing excellent immune protection levels against an otherwise lethal bacterial challenge.
Materials and Methods

Bacterial strains and plasmids
Trout CCL4 sequence (acc. number AY561709.1) was used to design specific cloning primers (Suppl. Table 1 ). The CCL4 full length was amplified from cDNA synthesized from trout head kidney total RNA purified using TriReagent (Sigma). The PCR product was excised from the gel, ligated into pET-30Xa/LIC vector (Novagen) and transformed into E. coli DH5α (Invitrogen). The CCL4-pET-30 Xa/LIC was then purified using the Nucleo-Spin Plasmid Quick-Pure (Macherey-Nagel), quantified using a Nanodrop ND-1000 (Thermo Scientific) and sequenced in order to check the sequence orientation.
Finally, for recombinant protein expression the CCL4-pET-30Xa/LIC was subcloned into E. coli BL21(DE3) pLysS strain. The bacterial strain used for the production of TNFα IBs was E. coli M15[pREP4] (Qiagen). This strain was transformed with the TNFα-pQE30 vector (Qiagen) as described [29] . CCL4-pET-30Xa/LIC and iRFP-H6-pET22b were transformed into E. coli BL21(DE3) for the recombinant production of were produced as control nanoparticles with irrelevant biological activity regarding immunostimulation. All the recombinant proteins contained a His-tag and could be detected by western blot using an anti-His tag antibody (GenScript).
IBs production, purification and fluorescent labelling
The E. coli transformed with TNFα-pQE30, CCL4-pET-30 Xa/LIC and iRFP-H6-pET22b were cultured in LB medium supplemented with required antibiotics.
Expression was induced when OD 550 nm reached 0.5 for 3 h at 1 mM of IPTG (Panreac).
For IB purification the bacterial cultures were processed through a combination of enzymatic and mechanical disruption. First, lysozyme at 1 μg/ml (Roche) and PMSF at 0.4 mM (Roche) were added to bacterial suspensions and incubated for 2 h at 37 °C and 250 rpm. Then, the cells were frozen and thawed and Triton X-100 (Sigma) was added (0.2 % (v/v)), the suspension was incubated 1 h under gentle agitation at RT. IBs were harvested by centrifugation and resuspended in PBS (10 times concentrated with respect to the original culture volume). Next, samples were incubated with DNAse at 0.6 µg/ml (Roche), 1 h at 37 °C under agitation. Several freeze/thaw cycles were carried out until no viable bacteria were detected. Samples were centrifuged at 15.000 x g for 15 min and pellets containing purified IBs stored at -80 °C until use. The IBs were quantified by western blot using an anti-His-tag antibody and the protein concentration was inferred from a standard curve made with recombinant protein.
To visualize IB 
Cell Cultures
Zebrafish ZFL cells (CRL-2643, ATCC) were cultured in DMEM 4.5 g/l glucose (Gibco), 0.01 mg/ml insulin, 50 ng/ml EGF, 5 % (v/v) of antibiotic/antimycotic, 10 % (v/v) heat inactivated FBS and 0.5 % (v/v) heat-inactivated rainbow trout serum at 28 ºC and 5 % CO 2 as described before [31] . Adherent rainbow trout head kidney macrophages (RT-HKM) were isolated from head kidney as described previously [29] and cultured in DMEM 4.5 g/l glucose supplemented with FBS (10 %) and 50 µg/ml Primocin (Invivogen) at 16 ºC and 5 % CO 2 . Fully differentiated macrophages (day 5)
were used for uptake and gene expression experiments.
Gene expression analysis
Rainbow trout macrophages (RT-HKM) were stimulated for 12 h with IB iRFP-H6 (10 µg/ml), LPS 10 µg/ml (Sigma), IB TNFα and IB
CCL4
at different concentrations (5, 10 and 20 µg/ml and 0.01, 0.1 and 1 µg/ml, respectively). Total RNA was extracted using TriReagent (Sigma) following manufacturer's instructions and the RNA concentration and quality were evaluated using the Nanodrop ND-1000 and the Bioanalyser-2100 with the RNA 6000 Nano Kit (Agilent Technologies) respectively. The cDNA synthesis was performed with 1 µg of total RNA using SuperScript III reverse transcriptase (Invitrogen) and oligo-dT 15 primer (Promega). Quantitative real-time PCR was carried out using SYBR Green I PCR Supermix (Bio-Rad), 250 nM of primers and 2.5 µl of cDNA previously diluted (1:50 for target and 1:500 for the reference gene) in 10 µl of final volume. The primers included in the study are listed in Supplementary Table 1 .
Elongation factor 1 alpha (EF1) was used as a reference gene and quantification was done according to Livak method [32] . The experiments were repeated 3 independent times and all samples were run in triplicate. The results were analyzed using one-way ANOVA followed by Tukey's post-test (GraphPad Prism). Adherent monocytes/macrophages were isolated from head kidney and spleen as described before [29] . In parallel, a piece of tissue was dissected and stored at -80 ºC for gene expression analysis. After 24 h of primary cell culture, cells were analyzed both by flow cytometry and confocal microscopy.
IBs uptake by ZFL and RT-HKM cells
In vivo immunization with TNFα and CCL4 IBs
Adult zebrafish (0.64 ± 0.17 g body weight) were transferred to an isolated system and acclimatized 1 day before each experiment. Pseudomonas aeruginosa (PAO1) was cultured and grown as previously described [33] . For IBs and PAO1 injection, fish were cfu/animal and their survival was followed for 7 days. Survival curves were analyzed using the KaplanMeier method and the differences were evaluated using the log-rank test (GraphPad Prism). Relative percentage of survival (RPS) was calculated according to RPS (%) = [(1 − mortality treated group)/mortality control group] × 100.
Oral administration of TNFα IBs
Rainbow trout (135.3 ± 16.8 g body weight) were starved three days before the administration of the IBs. Then, animals were anesthetized, orally intubated and 200 µl of IB TNFα -Atto488 (7.49 ± 0.97 mg/kg) were administrated. After 24 h rainbow trout were sacrificed by overdose of anesthesia and the intestine was removed and maintained in DMEM. The intestine was divided in three sections: pyloric caeca, midgut and hindgut (hindgut section was discarded). Cells from the intestine were obtained by enzymatic digestion with collagenase (0.15 mg/ml, Invitrogen) for 2 h at RT. After digestion, the intestine pieces were mechanically disrupted with a cell strainer and the resulting homogenate was centrifuged 15 min at 450 x g at 4 ºC. Then, the pellet was washed, resuspended in DMEM and analyzed by flow cytometry (100,000 events/sample). Additionally, pyloric caeca and midgut samples (n= 6) were embedded in Tissue-Tek O.C.T. Compound (Sakura), frozen and stored at -80 ºC. Sections of 0.6 µm were obtained at -20 ºC with a Cryostat (Leica CM3050S). Fluoroshield (Sigma) was added to every slide and all samples were analyzed by confocal microscopy. is also spherical but with a more irregular surface. Similar morphology has been described previously for other protein nanoparticles purified from IBs [11] . The size of Figure 1) . Finally, the confocal microscopy images enabled the visualization of the uptake by ZFL and the RT-HKM cells ( Figure 2B and 3B (i) ) and the 3D images demonstrated the complete internalization of IBs in ZFL and in RT-HKM ( Figure 2B and 3B (ii -iv)). [5] . Since we also wanted to test their suitability for oral administration, we determined IB stability under gastrointestinal pH conditions [30] . We also tested thermostability to demonstrate stable shelf life (high temperature and lyophilization). In general, we observed a similar shape of IB TNFα under different pH or the temperature treatments compared to untreated control ( Figure 7A and B) and a similar diameter and length distribution between control and pH treatment ( Figure 7A (ii -iii)). We only found significant differences in the diameter and length between the high temperature (diameter: 666.2 ± 84.2 nm, t-test, p < 0.0001; length:
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947.1 ± 186.4 nm, t-test, p < 0.0001) and the control condition (diameter: 623.3 ± 105 nm; length: 1134.6 ± 196.6 nm) ( Figure 7B (ii -iii) ). To further explore why the temperature was shortening the IBs, we checked the presence of protein in the supernatants of samples submitted to high temperature. The western blot confirmed that free/soluble protein was not present in the supernatants (data not shown) discarding our hypothesis of a potential massive release of protein from the nanostructure due to the drastic environmental change. Despite the size differences in the IBs incubated a high temperature, both IBs submitted to pH and temperature treatments were still able to stimulate the gene expression of immune related genes at equivalent levels to the same IBs under control conditions (Suppl. Figure 4) . We also evaluated whether fluorescent IB TNFα were able to maintain their fluorescence after incubation at low/high pH. As shown in Figure 7C , the RT-HKM were able to endocytose the pH treated IB TNFα -Atto488 IBs without differences with respect to control. Importantly, fluorescence intensity remained the same after the pH treatment, which would allow us to monitor fluorescent TNFα materials administrated orally. Finally, we analyzed the stability of IB TNFα after lyophilization, showing that this procedure did not modify the morphology as shape, size and porosity were maintained (Suppl. Figure 5A and 5B (i-ii)). Figure 8B (ii-iii) ). The IBs detected in the intestinal mucosa were able to form intracellular agglomerates of different sizes in the cytosol both in the pyloric caeca and midgut sections ( Figure 8B ).
Discussion
We have used two model cytokines and a model organism to test whether cytokine nanoparticles organized as functional IBs were suitable as immunostimulants or adjuvants for biomedical applications. In this work, we provide a proof of concept on the functionality and suitability of protein nanoparticles for their future possible use in human health. IBs are excellent candidates to be used as adjuvants, being highly stable, non-toxic and fully biocompatible under a wide range of conditions [7] . As shown in this study, IB TNFα maintained its stability and functionality after incubation under different conditions of pH and temperature, supporting the notion that IBs made of recombinant cytokines do not require additional encapsulation systems, since they are extremely stable in the nanostructured conformation. This is in sharp contrast to immunostimulants made with native cytokines that are extremely unstable (half-life of minutes). Indeed, when oral administration of such vaccines is desired, often the design has to include additional nanoencapsulation systems that provide protection under in vivo conditions [37, 38] . A variety of encapsulation methods, to protect vaccines or cytokines against degradation in the intestinal tract have been reported with promising results but, in most cases they are not yet cost effective [37, 39] . As IBs, cytokines are not only structurally stable, but they maintain their functional properties intact. Both of our prophylactic IBs, IB ). Importantly, the IBs final composition can be modulated using different E. coli strains (e.g. endotoxin free strains) together with "final purpose"-adapted purification methods [7, 40] . Our results strongly suggest that the immunological nature of the protein increases the protection conferred by the IBs, opening the way to explore other proteins, such as antigenic viral proteins for vaccine design.
From a commercial point of view it is also important to demonstrate the feasibility of the cytokine IBs pipeline production. In this context, the IBs did not modify their structural or functional properties after lyophilization, meaning that lyophilized IBs would not require cold-chain maintenance and could be stored and used at ambient temperatures. All these characteristics lower the cost of production of the final products and provide easy and convenient handling. Both, the structural and functional stability together with versatility would be the key for a future biomedical use of cytokines produced as IBs. When injected, IBs were able to reach and accumulate in immune relevant-organs (spleen and head kidney) and -cells (macrophages), as reported by other authors [33, 41] . The spleen is the major filtering organ for removal of foreign agents [42] and together with head kidney, are the main lymphoid organs in teleosts [43] . In addition, these are also the organs where phagocytes are more abundant and importantly, the spleen is the main organ for antigen presentation in teleosts [44, 45] . In mammals the spleen is also the main organ of antigen removal and recognition together with the lymph nodes and the thymus [46] . Moreover, our results strongly support the view that IBs could be excellent candidates for oral administration. After oral administration IBs were clearly uptaken and located in the villi base and submucosa within the pyloric caeca section and, in the villi apex and lamina propria within the midgut. Oral immunization provokes the activation of lymphocytes T and B and the antibody production in the mucosal secretions (e.g. skin mucus, bile, intestine mucus) [35, 47] . The main immune tissue involved in the uptake and processing of orally administrated antigens is the gut-associated lymphoid tissue (GALT). Teleosts possess the whole set of immune cells and molecules required for a GALT local immune response, although the global GALT structure is more diffuse than in mammals [48] . In teleosts the main effector sites in GALT are located in the lamina propria (LP) and in the intraepithelial lymphocyte compartments (IEL) while the classical effector sites (Peyer's patches and mesenteric lymph nodes MLNs) have only been described in mammals [49] . Fish do not have these structures but possess extrafollicular antigen presenting cells (APCs) that have been also described as inducer cells [50] . Accordingly, we detected fluorescent nanoparticles in the LP (midgut) and in the villi apex where IEL are located. The strong uptake ability of the midgut has an immune value, because it has been shown that antigens could be transported towards the local as well as systemic immune system [48, 51] . Based on our results, the IBs have been uptaken in the intestine maybe by IEL and APCs and stored intracellularly, probably stimulating mucosal immune responses. The nanostructure and stability of the IBs, together with the good levels of absorption by the intestinal mucosa favor the possibility of oral use.
Conclusions
In this study we were able to produce nanostructured, functional and highly stable cytokines as inclusion bodies (IBs), generating a fully biocompatible material with biomedical applicability, without further encapsulation needs. These cytokines, IB TNFα and IB
CCL4
, interact with relevant immune cells and tissues both when intraperitoneally injected or orally administrated, and provide in vivo excellent protection levels against a model lethal infection. These new biomaterials pave the way for using recombinant cytokines for therapeutical purposes in a more efficient and cost effective way. cfu/dose) (n = 15). Untreated zebrafish that had been infected with PAO1 were used as mortality control. Significant differences were analyzed using the log-rank test; **, p < 0.01; ***, p < 0.0001. cfu/dose) (n = 15). Untreated zebrafish that had been infected with PAO1 were used as mortality control. The control and lyophilized IB TNFα dose was 300 µg. Significant differences were analyzed using the log-rank test; **, p < 0.01; ***, p < 0.0001. Differences were analyzed using t-test. Significant differences respect to control ***, Table S1 . Rainbow trout primers for Q-PCR and CCL4 cloning. 
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